1CZ8
 
 | | VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH AN AFFINITY MATURED ANTIBODY | | Descriptor: | HEAVY CHAIN OF NEUTRALIZING ANTIBODY, LIGHT CHAIN OF NEUTRALIZING ANTIBODY, SULFATE ION, ... | | Authors: | Chen, Y, Wiesmann, C, Fuh, G, Li, B, Christinger, H.W, McKay, P, de Vos, A.M, Lowman, H.B. | | Deposit date: | 1999-09-01 | | Release date: | 2000-03-20 | | Last modified: | 2024-10-09 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
J.Mol.Biol., 293, 1999
|
|
4QCI
 | | PDGF-B blocking antibody bound to PDGF-BB | | Descriptor: | Platelet-derived growth factor subunit B, anti-PDGF-BB antibody - Light Chain, anti-PDGF-BB antibody - Heavy chain | | Authors: | Kuai, J, Mosyak, L, Tam, M, LaVallie, E, Pullen, N, Carven, G. | | Deposit date: | 2014-05-12 | | Release date: | 2015-03-11 | | Last modified: | 2024-10-30 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Characterization of Binding Mode of Action of a Blocking Anti-Platelet-Derived Growth Factor (PDGF)-B Monoclonal Antibody, MOR8457, Reveals Conformational Flexibility and Avidity Needed for PDGF-BB To Bind PDGF Receptor-beta.
Biochemistry, 54, 2015
|
|
1KAT
 | | Solution Structure of a Phage-Derived Peptide Antagonist in Complex with Vascular Endothelial Growth Factor | | Descriptor: | Phage-Derived Peptide Antagonist, Vascular Endothelial Growth Factor | | Authors: | Pan, B, Li, B, Russell, S.J, Tom, J.Y.K, Cochran, A.G, Fairbrother, W.J. | | Deposit date: | 2001-11-02 | | Release date: | 2002-11-02 | | Last modified: | 2022-02-23 | | Method: | SOLUTION NMR | | Cite: | Solution Structure of a Phage-derived Peptide Antagonist in Complex with Vascular Endothelial Growth Factor
J.Mol.Biol., 316, 2002
|
|
4WPB
 | | Vascular endothelial growth factor in complex with alpha/beta-VEGF-1 | | Descriptor: | Vascular endothelial growth factor A, alpha/beta-VEGF-1 | | Authors: | Kreitler, D.F, Checco, J.W, Gellman, S.H, Forest, K.T. | | Deposit date: | 2014-10-17 | | Release date: | 2015-04-15 | | Last modified: | 2024-07-10 | | Method: | X-RAY DIFFRACTION (3.11 Å) | | Cite: | Targeting diverse protein-protein interaction interfaces with alpha / beta-peptides derived from the Z-domain scaffold.
Proc.Natl.Acad.Sci.USA, 112, 2015
|
|
4ZFF
 | | Dual-acting Fab 5A12 in complex with VEGF | | Descriptor: | Fragment antigen binding (Fab) 5A12 Heavy chain, Fragment antigen binding (Fab) 5A12 Light chain, SULFATE ION, ... | | Authors: | Harris, S.F, Wu, P. | | Deposit date: | 2015-04-21 | | Release date: | 2015-07-01 | | Last modified: | 2015-09-16 | | Method: | X-RAY DIFFRACTION (2.75 Å) | | Cite: | Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.
J.Biol.Chem., 290, 2015
|
|
6V7K
 | |
3BDY
 | | Dual specific bH1 Fab in complex with VEGF | | Descriptor: | Fab Fragment -Heavy Chain, Fab Fragment -Light Chain, GLYCEROL, ... | | Authors: | Bostrom, J.M, Wiesmann, C, Appleton, B.A. | | Deposit date: | 2007-11-15 | | Release date: | 2008-11-18 | | Last modified: | 2023-08-30 | | Method: | X-RAY DIFFRACTION (2.6 Å) | | Cite: | Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
Science, 323, 2009
|
|
1FZV
 | | THE CRYSTAL STRUCTURE OF HUMAN PLACENTA GROWTH FACTOR-1 (PLGF-1), AN ANGIOGENIC PROTEIN AT 2.0A RESOLUTION | | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, PLACENTA GROWTH FACTOR | | Authors: | Iyer, S, Leonidas, D.D, Swaminathan, G.J, Maglione, D, Battisti, M, Tucci, M, Persico, M.G, Acharya, K.R. | | Deposit date: | 2000-10-04 | | Release date: | 2001-05-09 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2 Å) | | Cite: | The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 A resolution.
J.Biol.Chem., 276, 2001
|
|
1BJ1
 | | VASCULAR ENDOTHELIAL GROWTH FACTOR IN COMPLEX WITH A NEUTRALIZING ANTIBODY | | Descriptor: | Fab fragment, heavy chain, light chain, ... | | Authors: | Muller, Y.A, Christinger, H.W, De Vos, A.M. | | Deposit date: | 1998-06-30 | | Release date: | 1999-01-13 | | Last modified: | 2023-08-02 | | Method: | X-RAY DIFFRACTION (2.4 Å) | | Cite: | VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface.
Structure, 6, 1998
|
|
2C7W
 | | Crystal Structure of human vascular endothelial growth factor-B: Identification of amino acids important for angiogeninc activity | | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, VASCULAR ENDOTHELIAL GROWTH FACTOR B PRECURSOR | | Authors: | Iyer, S, Scotney, P.D, Nash, A.D, Acharya, K.R. | | Deposit date: | 2005-11-29 | | Release date: | 2007-01-30 | | Last modified: | 2024-10-23 | | Method: | X-RAY DIFFRACTION (2.48 Å) | | Cite: | Crystal Structure of Human Vascular Endothelial Growth Factor-B: Identification of Amino Acids Important for Receptor Binding
J.Mol.Biol., 359, 2006
|
|
1TZH
 | |
1TZI
 | |
2QR0
 | | Structure of VEGF complexed to a Fab containing TYR and SER in the CDRs | | Descriptor: | Fab-Fragment Heavy Chain, Fab-Fragment Light Chain, Vascular endothelial growth factor A | | Authors: | Wiesmann, C. | | Deposit date: | 2007-07-27 | | Release date: | 2007-08-14 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (3.5 Å) | | Cite: | High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries
J.Mol.Biol., 373, 2007
|
|
6D3O
 | |
5HHD
 | | Crystal Structure of Chemically Synthesized Heterochiral {RFX037 plus VEGF-A} Protein Complex in space group P21 | | Descriptor: | D-Peptide RFX037.D, D-Vascular endothelial growth factor, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Uppalapati, M, LEE, D.J, Mandal, K, Kent, S.B.H, Sidhu, S. | | Deposit date: | 2016-01-10 | | Release date: | 2016-03-09 | | Last modified: | 2024-11-06 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo.
Acs Chem.Biol., 11, 2016
|
|
4GLN
 | | Crystal Structure of Chemically Synthesized Heterochiral {D-Protein Antagonist plus VEGF-A} Protein Complex in space group P21/n | | Descriptor: | D-RFX001, Vascular endothelial growth factor A | | Authors: | Mandal, K, Uppalapati, M, Ault-Riche, D, Kenney, J, Lowitz, J, Sidhu, S, Kent, S.B.H. | | Deposit date: | 2012-08-14 | | Release date: | 2012-09-05 | | Last modified: | 2019-04-24 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography.
Proc.Natl.Acad.Sci.USA, 109, 2012
|
|
6T9D
 | | Crystal structure of a bispecific DutaFab in complex with human VEGF121 | | Descriptor: | VP mat DutaFab VH chain, VP mat DutaFab VL chain, Vascular endothelial growth factor A | | Authors: | Kimbung, R, Logan, D.T, Beckmann, R, Jensen, K, Speck, J, Fenn, S, Kettenberger, H. | | Deposit date: | 2019-10-28 | | Release date: | 2020-12-16 | | Last modified: | 2024-01-24 | | Method: | X-RAY DIFFRACTION (2.905 Å) | | Cite: | DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously.
Nat Commun, 12, 2021
|
|
5HHC
 | | Crystal Structure of Chemically Synthesized Heterochiral {RFX037 plus VEGF-A} Protein Complex in space group P21/n | | Descriptor: | D- Vascular endothelial growth factor-A, GLYCEROL, Vascular endothelial growth factor A | | Authors: | Uppalapati, M, Lee, D.J, Mandal, K, Kent, S.B.H, Sidhu, S. | | Deposit date: | 2016-01-10 | | Release date: | 2016-03-09 | | Last modified: | 2023-11-15 | | Method: | X-RAY DIFFRACTION (2.1 Å) | | Cite: | A Potent d-Protein Antagonist of VEGF-A is Nonimmunogenic, Metabolically Stable, and Longer-Circulating in Vivo.
Acs Chem.Biol., 11, 2016
|
|
4GLS
 | | Crystal Structure of Chemically Synthesized Heterochiral {D-Protein Antagonist plus VEGF-A} Protein Complex in space group P21 | | Descriptor: | D- RFX001, D- Vascular endothelial growth factor-A, DI(HYDROXYETHYL)ETHER, ... | | Authors: | Mandal, K, Uppalapati, M, Ault-Riche, D, Kenney, J, Lowitz, J, Sidhu, S, Kent, S.B.H. | | Deposit date: | 2012-08-14 | | Release date: | 2012-09-05 | | Last modified: | 2023-12-06 | | Method: | X-RAY DIFFRACTION (1.6 Å) | | Cite: | Chemical synthesis and X-ray structure of a heterochiral {D-protein antagonist plus vascular endothelial growth factor} protein complex by racemic crystallography.
Proc.Natl.Acad.Sci.USA, 109, 2012
|
|
6T9E
 | | Crystal structure of a bispecific DutaFab in complex with human PDGF | | Descriptor: | DutaFab mat VH chain, DutaFab mat VL chain, Platelet-derived growth factor subunit B | | Authors: | Kimbung, R, Logan, D.T, Beckmann, R, Jensen, K, Speck, J, Fenn, S, Kettenberger, H. | | Deposit date: | 2019-10-28 | | Release date: | 2020-12-16 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (2.989 Å) | | Cite: | DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously.
Nat Commun, 12, 2021
|
|
5FV2
 | | Crystal structure of hVEGF in complex with VH domain antibody | | Descriptor: | VASCULAR ENDOTHELIAL GROWTH FACTOR, VH DOMAIN ANTIBODY | | Authors: | Chung, C, Batuwangala, T. | | Deposit date: | 2016-02-02 | | Release date: | 2016-02-17 | | Last modified: | 2019-05-15 | | Method: | X-RAY DIFFRACTION (3.45 Å) | | Cite: | Novel Interaction Mechanism of a Domain Antibody Based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency Than Ranibizumab and Bevacizumab and Improved Capacity Over Aflibercept.
J.Biol.Chem., 291, 2016
|
|
5FV1
 | | Crystal structure of hVEGF in complex with VK domain antibody | | Descriptor: | VASCULAR ENDOTHELIAL GROWTH FACTOR A, VK DOMAIN ANTIBODY | | Authors: | Chung, C, Walker, A. | | Deposit date: | 2016-02-02 | | Release date: | 2016-02-17 | | Last modified: | 2019-05-15 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Novel Interaction Mechanism of a Domain Antibody Based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency Than Ranibizumab and Bevacizumab and Improved Capacity Over Aflibercept.
J.Biol.Chem., 291, 2016
|
|
2VPF
 | |
4HQX
 | | CRYSTAL STRUCTURE OF HUMAN PDGF-BB IN COMPLEX WITH A Modified nucleotide aptamer (SOMAmer SL4) | | Descriptor: | MAGNESIUM ION, Platelet-derived growth factor subunit B, SODIUM ION, ... | | Authors: | Davies, D.R, Edwards, T.E, Janjic, N, Gelinas, A.D, Zhang, C, Jarvis, T.C. | | Deposit date: | 2012-10-26 | | Release date: | 2012-11-21 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.3 Å) | | Cite: | Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets.
Proc.Natl.Acad.Sci.USA, 109, 2012
|
|
4HQU
 | | Crystal structure of human PDGF-BB in complex with a modified nucleotide aptamer (SOMAmer SL5) | | Descriptor: | MAGNESIUM ION, Platelet-derived growth factor subunit B, SODIUM ION, ... | | Authors: | Davies, D.R, Edwards, T.E, Janjic, N, Gelinas, A.D, Zhang, C, Jarvis, T.C. | | Deposit date: | 2012-10-26 | | Release date: | 2012-11-21 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (2.2 Å) | | Cite: | Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets.
Proc.Natl.Acad.Sci.USA, 109, 2012
|
|
